Integrated Platform for Early Detection and Therapeutic Intervention in Parkinson's Disease: Aptamers, Quantum Dots, and Trojan Horse Conjugates

AbstractThis work proposes an innovative therapeutic protocol for Alzheimer’s disease based on the use of the LAT1 transporter as a selective route for crossing the blood–brain barrier (BBB). The method consists of engineering a tripartite prodrug — composed of an amino acid vector, an enzyme‑responsive linker, and an antioxidant payload designed to modulate Tau protein — capable of entering the brain without compromising BBB integrity. After transporter‑mediated uptake, the complex is bioactivated exclusively within the neuronal intracellular environment, where it reduces oxidative stress, inhibits kinases associated with Tau hyperphosphorylation, and promotes the restoration of microtubule stability. The protocol also integrates a complementary intranasal route and a cyclic administration regimen to optimize cerebral bioavailability, minimize systemic toxicity, and preserve immunological homeostasis. This proposal was developed between April and August 2025, and the author retains documented evidence of the development timeline stored in e‑mail records. The present work is released into the public domain to encourage scientific collaboration and accelerate the advancement of targeted therapies for neurodegenerative disorders.